OZEMPIC® 0.5 mg Injectable (Semaglutide) – 1 Pre-filled Pen

OZEMPIC® 0.5 mg contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults with type 2 diabetes mellitus. It is supplied as a pre-filled injection pen designed for once-weekly subcutaneous administration.

Composition

• Active ingredient: Semaglutide
• Strength: 0.5 mg per dose
• Pharmaceutical form: Solution for injection
• Route of administration: Subcutaneous injection

Package Contents

• 1 pre-filled OZEMPIC® pen
• Disposable pen needles (quantity may vary by market)
• Patient information leaflet

Indications

OZEMPIC is used:

• To improve blood glucose control in adults with type 2 diabetes mellitus
• In combination with diet and exercise
• Alone or with other antidiabetic medications when appropriate
• To reduce the risk of major cardiovascular events in certain patients with type 2 diabetes and established cardiovascular disease (according to approved labeling)

Key Features

• Once-weekly dosing schedule
• Pre-filled, ready-to-use injection pen
• No reconstitution required
• Supports glycemic control through GLP-1 receptor activation
• May contribute to weight reduction in some patients as part of diabetes management

Administration

• Administered once weekly by subcutaneous injection
• Can be injected into the abdomen, thigh, or upper arm
• Should be used exactly as prescribed by a healthcare professional

Storage

• Store refrigerated at 2°C–8°C before first use
• Do not freeze
• Protect from excessive heat and direct light
• Follow manufacturer instructions regarding storage after first use

Packaging

• Product: OZEMPIC®
• Active Substance: Semaglutide
• Strength: 0.5 mg
• Presentation: Pre-filled injection pen
• Pack Size: 1 pre-filled pen

Manufacturer: Novo Nordisk

Note: OZEMPIC is a prescription medicine and should only be used under the supervision of a qualified healthcare professional. Patients should follow prescribed dosing instructions and recommended lifestyle measures to achieve optimal treatment outcomes.